Our findings demonstrate that SMC5/6 complex disruption in cancer predicts elevated TMB and susceptibility to immunotherapy, indicating the potential to use SMC5/6 gene status for prognostic implications and tailored therapeutic approaches. Here, SMC5 is linked to cancer.